Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Even Greater Stabilization in Patients Starting Earlier Treatment - Post Register
[unable to retrieve full-text content] Progress on Cardiovascular Disease Care in the U.S. Has Stalled Despite Treatment Advances, New Report Finds The Harvard Crimson
Comments
Post a Comment